Podcasts about ckd

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You'll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust medication doses in kidney disease.Special guests:Erin F. Barreto, PharmD, PhD, FCCM, FASN, BCCCPAssociate Professor of Medicine and PharmacyMayo ClinicTracy Anderson-Haag, PharmD, BCPS, BCTXPClinical Pharmacy Specialist-TransplantationResidency Program Director, PGY-2 Solid Organ TransplantHennepin HealthcareNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in June 2026.

An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD.

In 11,409 adults with CKD and no prior heart failure, three standard ECG features independently predicted new-onset HF hospitalization. The findings support routine ECG as a low-cost adjunct to existing HF risk assessment in CKD.

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) examines how to optimize the use of time-tested gout therapies in today's increasingly complex patients. Through practical case discussions, our expert faculty will address colchicine safety and dosing in chronic kidney disease, selecting first-line therapy for acute flares, initiating and titrating urate-lowering therapy, improving treatment adherence, and navigating challenging scenarios such as gout management in patients with CKD and cardiovascular disease. Panelist: Dr. Angelo Gaffo  Dr. Lisa Stamp  Dr. Michael Pillinger  Dr. Ted Mikuls  Moderator: Dr. Jack Cush

Starting dialysis often means rethinking your relationship with food—and that includes eating out. But dining out doesn't have to be off-limits. In this episode, we're talking about the emotional and practical sides of dining out, from advocating for yourself at restaurants to balancing dietary needs with quality of life. In today's episode we heard from: Lauren Levy is the practice owner and principal dietitian in an insurance based private practice that focuses on kidney health. Lauren bills insurance companies, works with CKD patients and nephrologists on a daily basis to prevent progression of CKD. Melissa Bensouda was diagnosed with chronic kidney disease after giving birth to her second daughter. After her third child, she had lost all functionality of her kidneys. She was placed on the transplant wait list in June of 2002. Although Melissa initially began dialysis treatments in-center, she was selected to participate in a nocturnal home hemodialysis program. After 6 weeks of extensive training, Melissa set up a machine in her bedroom and dialyzed on her own every other night for 8 hours while she slept. She received the gift of freedom from a deceased donor in April of 2012. Nearly five years post-transplant, Melissa's transplant kidney rejected, causing her to resume dialysis at home. Melissa's passion and commitment to awareness has been revived following such an extensive journey. Despite working full-time and raising three children, Melissa is determined to continue advocating for technology, education, and research to improve outcomes of those affected by kidney disease.  Additional Resources Nutrition for Kidney Patients Dining Out With Confidence Info Cronometer   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Have you heard of Farxiga (dapagliflozin), Jardiance (empagliflozin), Ozempic, Wegovy, Mounjaro, or finerenone, but aren't quite sure what they do or whether they're right for people living with kidney disease?   In this episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Professor Alex, Consultant Nephrologist and researcher, for an essential conversation about some of the biggest breakthroughs in kidney medicine in recent years.   Originally developed for diabetes, SGLT2 inhibitors have transformed kidney care and are now helping to protect kidney function, reduce protein in the urine and improve outcomes for many people living with chronic kidney disease (CKD). We also explore the growing role of GLP-1 receptor agonists and finerenone, and explain what patients need to know about these treatments.   Whether you're living with chronic kidney disease, caring for someone who is, or you're a healthcare professional wanting a patient-friendly explanation, this episode is packed with practical, evidence-based information.   In this episode, you'll learn:   ✅ What SGLT2 inhibitors are and how they protect the kidneys ✅ Why medications developed for diabetes are now transforming kidney care ✅ How GLP-1 receptor agonists (including Ozempic, Wegovy and Mounjaro) may benefit kidney health ✅ What finerenone is and who may benefit from it ✅ Why your eGFR may temporarily fall after starting treatment—and why this isn't always a cause for concern ✅ The benefits and possible side effects of these medications ✅ Which kidney patients may be suitable for these treatments ✅ The latest developments in kidney research and future treatments   This episode shares expert insight designed to educate, empower and inspire people living with kidney disease and those who support them.  

CKDの日常診療のアップデートに役に立つ情報を発信しています。

CME credits: 0.25 Valid until: 14-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/ A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD), including those without diabetes. Through expert analysis of key studies and a patient perspective, the faculty explore the evolving cardiorenal landscape, practical implications for clinical practice, and opportunities to address persistent unmet needs across the CKD spectrum.=

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-493 Overview: Chronic kidney disease (CKD) is increasingly managed in primary care—but are you up to date on the latest guidance? This episode reviews current clinical practice guidelines and standards of care to help you confidently diagnose and classify CKD, apply evidence-based management strategies, and know when nephrology referral is warranted. Episode resource links: https://doi.org/10.7326/ANNALS-25-03499 Diabetes Care. 2024;48(Supplement_1):S239-S251. doi:10.2337/dc25-S011 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-493 Overview: Chronic kidney disease (CKD) is increasingly managed in primary care—but are you up to date on the latest guidance? This episode reviews current clinical practice guidelines and standards of care to help you confidently diagnose and classify CKD, apply evidence-based management strategies, and know when nephrology referral is warranted. Episode resource links: https://doi.org/10.7326/ANNALS-25-03499 Diabetes Care. 2024;48(Supplement_1):S239-S251. doi:10.2337/dc25-S011 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

What happens when a childhood kidney condition goes undiagnosed for years?   In this powerful episode of Diary of a Kidney Warrior Podcast, host Dee Moore speaks with Noël, who was born with vesicoureteral reflux (VUR), also known as kidney reflux. Although she experienced repeated urinary tract infections (UTIs) throughout childhood, her condition wasn't diagnosed until she was seven years old. By then, irreversible kidney damage had already occurred, leading to chronic kidney disease (CKD).   Noël shares her remarkable Kidney Warrior journey—from growing up with chronic kidney disease, to unexpectedly crash landing onto dialysis, and ultimately receiving the life-changing gift of a kidney transplant.   This honest, emotional and inspiring conversation explores the realities of living with kidney disease, navigating childhood and adulthood with a lifelong condition, advocating for your health, and finding hope through resilience and community.   In this episode, we discuss:  

A CFMOTO chegou ao mercado brasileiro de motos em 2026 com um modelo diferente. Na live de lançamento em 28 de maio, 600 motocicletas foram reservadas em menos de 40 minutos. Agora a marca segue com aberturas de lotes controlados, mantendo a lógica de reservas digitais e preço único.Os modelos disponíveis são o CLC 450 (R$ 32.990), CLC 450 Bobber (R$ 33.990), IBEX 450 (R$ 35.990) e IBEX 700 (R$ 44.990). Todas as motos saem de fábrica com lubrificantes Motul e contam com 3 anos de garantia sem limite de quilometragem.A marca estabeleceu uma parceria estratégica com a Motul (lubrificante oficial) para padronizar a qualidade técnica em toda a rede de pós-venda. A produção ocorre em Manaus, em regime CKD (montagem desmontada).O diferencial da CFMOTO é a aposta em transparência, sem negociação de preços, com acesso igualitário e crescimento controlado respeitando a capacidade produtiva. Neste vídeo, conversamos sobre como essa estratégia mudou a forma como a marca se posiciona no mercado de duas rodas brasileiro.Entrevista gravada em 2 de julho de 2026.Fale conosco! Mande e-mail para contato@motordomundo.com.brSiga nosso Instagram!⁠⁠⁠ www.instagram.com/motordomundo

CKD Food Rules That Need an Update Kidney nutrition has a reputation for being restrictive, confusing, and honestly… a little intimidating. But for many patients with chronic kidney disease, the biggest problem isn't that they're eating a banana or adding tomatoes to dinner. It's that they've been handed outdated food rules that leave them scared to eat.In this episode, I'm joined by renal dietitian Lauren Budd Levy, MS, RDN, CSR, to talk about what clinicians need to know about kidney nutrition, especially if you don't work in nephrology.We cover the CKD diet rules that need an update, including potassium restriction, phosphorus additives, protein needs, sodium, hydration, electrolyte powders, and how to help patients enjoy summer cookouts, travel, and real life without feeling like their kidney diagnosis means they have to avoid everything.Key Takeaways:Why “avoid bananas, potatoes, tomatoes, oranges, and avocados” is often too simplistic  The easy label-reading tip patients can use to spot phosphorus additives  How to talk about protein needs in CKD without fueling confusion from high-protein diet culture  Why sodium reduction does not mean a no-salt, flavorless diet  What to tell patients about electrolyte powders, hydration, cookouts, and kidney-friendly travel snacks If your patient with CKD has ever asked, “Can I eat tomatoes?” “Do I need to avoid phosphorus?” or “Are electrolyte drinks safe for me?” this episode will help you answer with more confidence, nuance, and compassion.Resources Mentioned: Episode 43 | Nutrition and Kidney Disease: What's a Renal Diet?Episode 32 | How to Read a Nutrition Facts Label - with a Focus on Kidney HealthConnect with LaurenAny Questions? Send Me a MessageSupport the showConnect with Colleen:InstagramLinkedInSign up for my FREE Newsletter - Nutrition hot-topics delivered to your inbox each week.Disclaimer: This podcast is a collection of ideas, strategies, and opinions of the author(s). Its goal is to provide useful information on each of the topics shared within. It is not intended to provide medical, health, or professional consultation or to diagnosis-specific weight or feeding challenges. The author(s) advises the reader to always consult with appropriate health, medical, and professional consultants for support for individual children and family situations. The author(s) do not take responsibility for the personal or other risks, loss, or liability incurred as a direct or indirect consequence of the application or use of information provided. All opinions stated in this podcast are my own and do not reflect the opinions of my employer. 

Cohort studies have played a pivotal role in advancing our understanding of chronic kidney disease (CKD), providing invaluable insights into disease progression, risk factors, and patient outcomes. In this episode of the Global Kidney Care Podcast, host Maarten Taal is joined by Roberto Pecoits-Filho and Natalia Alencar de Pinho to discuss the principles behind designing and conducting high-quality CKD cohort studies, drawing on the collective experience of the International Network of CKD Cohort Studies (iNET-CKD).The conversation explores what makes cohort studies uniquely valuable in nephrology, the practical challenges of establishing and maintaining long-term cohorts, and the lessons learned from decades of collaborative research. The speakers also reflect on the importance of international partnerships, discussing how networks such as iNET-CKD enable researchers to address questions that no single cohort could answer alone while strengthening kidney research across diverse healthcare settings.Looking ahead, the discussion considers how CKD cohort studies are evolving to meet emerging research priorities and what the next decade may hold for observational kidney research. Listeners will gain insights into why sustained collaboration, robust study design, and global data sharing remain essential for improving outcomes for people living with CKD.HostMaarten TaalFormer Chair of the ISN International Network of CKD Cohort Studies (iNET-CKD) and current Deputy Chair of the ISN Research Working Group. Professor of Medicine at the University of Nottingham, UK, Professor Taal is a leading nephrologist whose research focuses on the epidemiology and progression of chronic kidney disease, with a particular interest in CKD cohort studies, international research collaboration, and improving outcomes for people living with kidney disease.GuestsRoberto Pecoits-FilhoChair of the ISN International Network of CKD Cohort Studies (iNET-CKD). Originally from Brazil and currently based in the United States, Dr. Pecoits-Filho is a leading nephrologist and researcher who has been instrumental in building global collaborations that advance research and knowledge in chronic kidney disease.Natalia Alencar de PinhoDeputy Chair of the ISN International Network of CKD Cohort Studies (iNET-CKD) and Clinical Epidemiologist at Paris-Saclay University and Inserm, France. She is also the Principal Investigator of the CKD-REIN cohort study, with research focusing on CKD epidemiology, cohort studies, and the evaluation of clinical practices.To learn more about the ISN International Network of CKD Cohort Studies (iNET-CKD), visit the iNET-CKD page here.To read the perspective paper on The Design and Conduct of Cohort Studies of Peoples With CKD – International Perspectives From iNET-CKD, published in Kidney International Reports.

Beyond hemodynamics: rewriting the future of nondiabetic CKD care. Credit available for this activity expires: 6/19/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/https://www.medscape.org/viewarticle/hot-press-new-evidence-emerging-therapies-nondiabetic-ckd-2026a1000k2g?ecd=bdc_podcast_libsyn_mscpedu

This episode walks through how chronic kidney disease (CKD) can be silent, what kidney disease symptoms to watch for, and when to seek specialist care. Dr. Fausto Cabezas Bolanos, MD (board‑certified nephrologist and internist at Jamaica Hospital Medical Center) explains how simple tests can check your kidney function and help with early detection of CKD. Keywords: chronic kidney disease, CKD, kidney function, kidney disease symptoms, nephrologist, early detection. Learn more or schedule an appointment at jamaicahospital.org.

Dr. Fan-Chi Chang discusses findings from her study, "Cell-Specific Roles of Angiopoietin-2 in CKD," with JASN Deputy Editor Alan S.L. Yu.

Plant-based nutrition has emerged as an important component of kidney care, but questions remain about how plant-based enteral formulas can best support people living with chronic kidney disease (CKD). In this episode of Kidney Commute: Pit Stop, host Dr. Raphy Rosen is joined by Brandon Kistler, PhD, RD, and Rachel Wontor, MS, RDN, CD, CNSC, to explore the growing role of plant-based enteral nutrition in clinical practice. The discussion examines the key features of plant-based formulas, including standard, renal-specific, peptide, and specialty options, and reviews how these products compare with traditional formulas in meeting nutritional needs. The panel also discusses when renal formulas may or may not be necessary, current evidence related to effectiveness and patient acceptance, insurance coverage considerations, and practical approaches for implementing plant-based enteral nutrition in healthcare settings. Clinicians will gain actionable insights to help support individualized nutrition care for people with CKD. After listening to the podcast, please take a moment to complete the quick survey at https://nkf.jotform.com/261534175734863 

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. Lots going on in this new episode! Three new pieces of research and an interview with Dr Anna Martinez, consultant paediatric dermatologist at GOSH, talking about a skin fragility condition many of us may not have heard of before - epidermolysis bullosa - in conjunction with DEBRA, the leading charity for EB awareness and research. In research, we look at two papers published this week in finerenone. Does it have a role in CKD management in patients without diabetes, and if so, how good is it?Second, retatruide - the latest injectable weight loss medication making a splash across the headlines - could it be used as monotherapy for recent onset type 2 diabetes?ResourcesNB Medical Epidermolysis bullosa free online educational moduleDEBRANEJM Finerenone for CKDLancet Finerenone MALancet Retatrutide for early T2DMwww.nbmedical.com/podcast

In this powerful episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Rebecca Griffiths, who shares her extraordinary journey through kidney failure, dialysis, kidney transplantation and transplant loss.   Rebecca's story is one of resilience, determination and hope. After gaining approximately 25kg of fluid in a matter of days and requiring emergency treatment to drain fluid from around her heart, she found herself facing kidney failure without the support of a renal team. What followed was a life-changing journey that included dialysis, a kidney transplant, the devastating loss of that transplant and the challenge of starting again.   In this episode, Rebecca discusses:  

GFR is one of the most important kidney lab values to know for NP boards because it tells you how well the kidneys are functioning and helps determine chronic kidney disease staging. In this minisode, I break down the key GFR cutoffs, explain how to think of CKD stages as a simple ladder, and review the clinical decisions that often show up on exams, including medication adjustments, kidney protection strategies, and when dialysis becomes necessary.          Follow us on Instagram: instagram.com/smnpreviewsofficial

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

What if we could cut hospitalizations nearly in half—before symptoms even show up? Kelly Constable, CEO of CloudCath, is making that a reality with a breakthrough remote monitoring platform that detects infections early for dialysis patients—replacing subjective, manual checks with continuous, data-driven insight at home. In this episode, Kelly shares how CloudCath is transforming chronic kidney disease (CKD) care by enabling earlier intervention, reducing hospitalizations, and helping patients stay out of the ER while preserving quality of life. She dives into the power of real-world data, the shift toward home-based and value-driven care, and why scalable, tech-enabled solutions are essential in the face of workforce shortages. We also explore the business of healthcare innovation—from building the right board and network to commercializing medtech and scaling adoption in complex ecosystems. Topics: remote patient monitoring, chronic kidney disease (CKD), home dialysis, early infection detection, digital health innovation, AI and data in healthcare, value-based care, medtech commercialization

Early detection of chronic kidney disease (CKD) means little if it does not lead to timely treatment, yet a significant gap persists between when CKD is found and when evidence-based therapies are started. That disconnect is the focus of the second episode of Beyond the Silo: Integrated Care Across the CRM Continuum, a podcast series from The American Journal of Managed Care®, in which Ralph Riello, PharmD, BCPS, leads a conversation with Nihar Desai, MD, MPH, on how to shift CKD care from a reactive, late-stage model to one that is proactive, pathway-driven, and equitable. The discussion builds on the first episode's focus on urine albumin-to-creatinine ratio underutilization, stipulating that screening has occurred and asking what must happen next. You can listen to the first episode here: https://www.ajmc.com/link/89943

https://www.patreon.com/highyieldfamilymedicineIntro (0:35),Definition and KDIGO Staging (1:47),Screening for CKD (4:30).Diabetic Nephropathy (6:22),Hypertensive Nephrosclerosis (8:17),Nephrotoxic Medications (9:53),Autosomal Dominant Polycystic Kidney Disease (12:07),IgA Nephropathy (14:06),Minimal Change Disease (15:06),FSGS (15:55),Membranous Nephropathy (16:26),Anemia of CKD (16:52),Mineral Bone Disorder (18:40),Hyperkalemia (21:11),Metabolic Acidosis (23:40),Volume Overload (25:25),Uremia (25:50),Renal Replacement Therapy (28:35),Practice Questions (31:43)

Phosphate additives are commonly used in processed and convenience foods, yet many patients and healthcare professionals remain unaware of how significantly they contribute to phosphorus burden in chronic kidney disease (CKD). Elevated phosphorus levels can negatively impact bone, cardiovascular, and overall kidney health, making phosphorus management an important aspect of kidney care. In this episode of Kidney Commute, an interprofessional panel featuring a nephrologist, dietitian, policy expert, and patient advocate discusses the clinical impact of phosphate additives, the differences between naturally occurring phosphorus and additive-based phosphorus, and the practical challenges patients face when trying to identify hidden phosphorus sources in foods and medications. The discussion also explores socioeconomic barriers, food labeling limitations, and ongoing policy and advocacy efforts aimed at improving phosphorus transparency and patient education. Listeners will gain practical strategies and insights to better support phosphorus management in clinical practice and daily life.

Welcome to another episode of Diary of a Kidney Warrior Podcast. In this powerful Kidney Warrior Story episode, host Dee Moore is joined by Johanna, who shares her lifelong journey living with Chronic Kidney Disease (CKD). Diagnosed as a young child after years of unexplained symptoms, Johanna opens up about growing up with kidney disease, navigating dialysis, experiencing transplant loss, and undergoing multiple kidney transplants. She speaks honestly about the physical and emotional realities of living with CKD for decades, including the uncertainty that comes with transplantation and the challenges of returning to dialysis. Johanna also shares the impact kidney disease has had on her mental wellbeing, family life, pregnancy, identity, and future plans. Throughout the conversation, she highlights the importance of resilience, support, advocacy, and finding joy in life despite the ongoing challenges of chronic illness. This episode is an honest and deeply moving insight into the realities of long-term kidney disease and the strength it takes to keep moving forward through every stage of the journey. In this episode, Johanna discusses: Being diagnosed with kidney disease as a child Growing up with CKD The symptoms that led to diagnosis Starting dialysis Receiving her first kidney transplant The emotional impact of transplant loss Returning to dialysis Undergoing further kidney transplants Pregnancy after transplantation The uncertainty of living with CKD Mental health and emotional resilience Finding hope whilst living with chronic illness If you are living with kidney disease, supporting someone who is, or want to better understand the realities of CKD, this episode is not to be missed.

Building on the concepts introduced in the previous episode Rethinking the Design and Conduct of Kidney Trials, this episode explores how innovative ideas in nephrology research can be translated into practical trial strategies. Experts discuss novel approaches to trial design, evolving endpoint selection, and the importance of engaging patients, clinicians, regulators, and other stakeholders throughout the research process. Drawing on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024), the discussion highlights how more pragmatic and implementation-focused trials can help generate evidence that is meaningful for clinical practice and patient care worldwide. Speakers Adeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. David Wheeler Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free Hospital. His research focuses on the management of chronic kidney disease and the evaluation of therapies through large-scale clinical trials. He was co-principal investigator of the landmark DAPA-CKD trial and served as Co-Chair of KDIGO from 2012–2019.  Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International. 

CME credits: 0.25 Valid until: 21-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-the-latest-kdigo-guidelines-into-practice-iv-iron-therapy-in-patients-with-nondialysis-dependent-ckd/54631/ Iron deficiency and iron-deficiency anemia are related but distinct clinical entities, with iron deficiency often preceding or occurring independently of anemia. In chronic kidney disease (CKD), inflammation-driven iron sequestration and impaired iron availability frequently develop before hemoglobin declines, making hemoglobin-only screening insufficient. Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD highlight the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD, along with the need for proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selection of iron replacement strategies to improve long-term patient outcomes. =

In today’s VETgirl online veterinary continuing education podcast, Dr. Ragen T.S. McGowan, Pet Behaviorist at Purina, discusses how veterinarians and pet owners can use at-home pet tech like activity trackers and litter box analytics to detect early signs of diseases such as CKD and arthritis. She highlights real examples, client engagement strategies, realistic device expectations, and the promising future of smart pet technology in veterinary care.Sponsored By: Purina

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. More new research to discuss for the world of general practice.First, which antibiotic is actually best for managing uncomplicated UTI - is UK guidance offering the best choice to women?Second, are you using the Kidney Failure Risk Equation in your patients with CKD? New research on how your risk of death may be much more important than your risk of end-stage renal disease.Finally, does empathy work in telephone consultations, and can it improve important hard outcomes such as symptom control?ReferencesLancet Abx for UTIBJGP Kidney Failure Risk Equation, Death and ESRDKidneyfailurerisk.co.ukBJGP Empathy and the telephoneCARE measurewww.nbmedical.com/podcast

CME credits: 1.00 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/aldosterone-targeted-therapies-uncontrolled-hypertension-chronic-kidney-disease/56405/ Chronic kidney disease (CKD) and high blood pressure (BP) are closely linked and, when not managed appropriately, can lead to serious outcomes such as myocardial infarction, stroke, heart failure, and progression to kidney failure. Pathological excess of aldosterone induces hypertension by forcing the kidneys to excessively retain sodium and water, increasing blood volume, and lowering potassium. Mineralocorticoid receptor antagonists (MRAs), which target the renin-angiotensin-aldosterone system (RAAS), do not fully inhibit the deleterious effects of aldosterone and may increase serum aldosterone concentrations. Highly selective aldosterone synthase inhibitors (ASIs) have emerged as potential alternatives to MRAs; ASIs decrease aldosterone synthesis, providing another strategy to inhibit aldosterone effects without affecting cortisol production.Want to dive deeper into the discussion? Check out Audience Q&A From the Live Symposium in the Related Content section for additional expert insights and practical perspectives on CKD, hypertension, and emerging aldosterone-targeted therapies. =

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: -Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health -Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine. Selected references: -Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 -Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 -Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 -Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

Anemia in chronic kidney disease remains common, complex, and rapidly evolving. In this episode, experts discuss key updates from the 2026 KDIGO Clinical Practice Guidelines and AJKD commentary, including a stronger focus on identifying and treating iron deficiency and refining treatment strategies. The conversation explores the clinical impact of anemia on cardiovascular risk and quality of life, reviews evidence supporting proactive IV iron use, and examines emerging therapies such as HIF stabilizers. The panel also addresses real world challenges in managing anemia, particularly in non dialysis CKD populations, where access, adherence, and care coordination play a critical role. This episode provides practical insights to support individualized, evidence based anemia care. Please click here to access the commentary.

Chronic kidney disease (CKD) affects an estimated 37 million Americans, yet most cases go undiagnosed until the disease has significantly progressed. A urine albumin-to-creatinine ratio (uACR) test can detect kidney damage years before a decline in the estimated glomerular filtration rate (eGFR), but it remains underutilized. In the first episode of Beyond the Silo: Integrated Care Across the CRM Continuum, a podcast series from The American Journal of Managed Care®, Marc P. Bonaca, MD, MPH, moderates a discussion with Josephine Harrington, MD, on why uACR has not yet become a standard of care, how CKD fits into the broader cardio-renal-metabolic (CRM) disease continuum, and what changes are needed across specialties, systems, and workflows. Bonaca is a cardiologist and vascular medicine specialist at the University of Colorado Anschutz and the executive director of CPC Clinical Research. Harrington is also a cardiologist, specializing in advanced heart failure and transplant cardiology at UCHealth's Heart and Vascular Center at the University of Colorado Hospital. Throughout the conversation, they emphasize that CKD is an early integral part of the CRM continuum, as it is both a driver and consequence of cardiovascular risk, with uACR elevation often appearing before eGFR decline and signaling increased risk even at mild levels. Despite strong guideline support, uACR screening remains underused due to structural barriers. Therefore, the experts explained that the primary barrier is not the test itself but the lack of streamlined workflows that make screening routine and results actionable without adding clinician burden. They concluded that early detection is critical because it enables the timely use of therapies such as SGLT2 inhibitors, glucagon-like peptide-1 receptor agonists, and finerenone, which improve outcomes. To close the gap, the experts noted that uACR should be treated as a routine vital sign for cardiometabolic risk and embedded into health system quality metrics to ensure consistent, accountable use.

This podcast discusses a post hoc analysis of the STOP-ACEi trial, examining whether baseline loop diuretic use modifies the effect of Renin–Angiotensin System Inhibitors in advanced CKD.

BP Lowering in CKD: Consistent. Comprehensive. Compelling.

Kidney care rarely takes center stage in Congress, but a recent hearing is bringing renewed attention to prevention, innovation, and patient access. In this episode, host Raphy Rosen is joined by Dr. Suzanne Watnick, who testified as a witness at the March 18 Ways and Means Health Subcommittee hearing, along with Dr. Dan Weiner. Together, they unpack key themes across CKD, dialysis, and transplantation, and explore what emerging legislative efforts could mean for patients and providers. Tune in for an inside look at how kidney care is shaping national health policy.

Please visit answersincme.com/860/101064703-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Muthiah Vaduganathan, MD, MPH and Nosheen Reza, MD, MS. In this activity, experts in cardio-kidney-metabolic syndrome (CKM) discuss emerging evidence on nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and practical strategies for incorporating these therapies into care for patients with heart failure, with or without chronic kidney disease (CKD) or type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Specify the rationale for nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) as treatment for adult patients with HF, with or without CKD or T2D; Differentiate the risk-benefit profiles between nsMRAs and the current standard of care for the treatment of HFmrEF or HFpEF, based on the available evidence; and Recommend patient-centered, long-term care strategies to integrate nsMRAs into clinical practice for patients with HF, with or without overlapping CKD or T2D.

What does the difference a year make? Less than a year ago, Cam was in hospital — so unwell that he didn't want his children to see him. Now… he's preparing to run a marathon and attempt a world record. In this powerful episode of Diary of a Kidney Warrior Podcast, Cam shares his journey from a seemingly minor ear infection… to crashing into emergency dialysis with no warning, no preparation, and his life turned upside down overnight.   This is a story about shock, survival, and what it really takes to rebuild your life after a diagnosis you never saw coming.  

Dalam Keluar Sekejap Episod 193, perbincangan tertumpu kepada konflik yang semakin memuncak antara AS–Israel dan Iran, serta implikasi geopolitik dan ekonomi yang mungkin dirasai oleh Malaysia.Turut disentuh ialah kontroversi melibatkan ahli perniagaan Victor Chin, yang mendakwa kewujudan rangkaian “mafia korporat” berkait urusan NexG Bhd, termasuk dakwaan tentang seorang perantara dikenali sebagai “Mr R” yang dikaitkan dengan pembayaran RM9.5 juta.Selain itu, episod ini membincangkan laporan mengenai BYD yang didakwa menilai semula rancangan membuka kilang pemasangan CKD di Tanjong Malim, susulan syarat yang dikatakan dikenakan oleh MITI, walaupun kementerian tersebut telah menafikan dakwaan berkenaan.Episod ini juga menyentuh insiden kemalangan maut akibat pemandu mabuk di Klang, yang meragut nyawa Amirul Hafiz Omar (33), seorang bapa kepada tiga orang anak, dan kembali mencetuskan perbahasan tentang penguatkuasaan serta keselamatan jalan raya.Ingin jenama anda dikenali oleh ribuan pendengar?Taja episod Keluar Sekejap 2026!Hubungi +6011-1919 1783 atau emel commercial@ksmedia.my

What is it like to be diagnosed with polycystic kidney disease (PKD) at just 10 years old—and to know it runs through your family?   In this powerful episode of Diary of a Kidney Warrior Podcast, Dee Moore speaks with Natasja about her lived experience of PKD, a hereditary kidney condition that has affected multiple generations of her family.   From her great-grandmother to her mother and beyond, kidney disease is not just part of Natasja's story, it's part of her family history.   In this honest and deeply personal conversation, Natasja shares what it's like growing up with chronic kidney disease (CKD), navigating the emotional and physical realities of a lifelong condition, and facing serious complications along the way.   In this episode, we cover: What polycystic kidney disease (PKD) is Being diagnosed with kidney disease at a young age The impact of hereditary kidney disease across generations Living with chronic kidney disease (CKD) Navigating serious health complications Finding strength through lived experience   ⚠️ Content note: This episode includes discussion of serious complications related to kidney disease that some listeners may find difficult.   This episode is a powerful reminder that behind every diagnosis is a real story, one of resilience, strength, and lived experience.   Follow Diary of a Kidney Warrior:  

If you have chronic kidney disease, you've probably been told to cut out potassium, avoid phosphorus-rich foods, and brace for dialysis. But what if most of that advice is outdated and the foods you've been avoiding are actually the ones that could protect your kidneys?In this episode, you'll hear from Jen Hernandez RDN, CSR, LDN, who makes the case that the most powerful thing people with CKD can do isn't eliminate more foods, but stop fearing the ones that were never the problem to begin with.Connect with Destiny:  Instagram / Facebook______________________________

Hosted by Dr. Sam Kant, this Kidney Commute: Pit Stop episode explores the Cerebronephrology region of NephMadness 2026 and the emerging concept of the brain–kidney axis. Drs. David Drew and Colton Jensen examine how chronic kidney disease and ESKD with dialysis contribute to cognitive impairment—an underrecognized complication affecting a large proportion of patients. From early microvascular injury, albuminuria, and hypertension in CKD to cerebral hypoperfusion, ischemia, and structural brain changes during dialysis, this discussion highlights the bidirectional relationship between kidney and brain health. Join us as we unpack where brain injury begins and what this means for earlier recognition and improved patient care.

 In this episode, Dr. Annoushka Ranaraja  discusses the relationship between Chronic Kidney Disease and osteoporosis based on a case study of a 68 yo female with CKD who sustained a pelvic fracture. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7555655/ Want to make sure you stay up to date in all things Geriatrics in less than 3 minutes every other week? Join thousands of others in our free MMOA Digest Email list - https://institute-of-clinical-excellence.kit.com/a3837f54b7

Chronic kidney disease (CKD) now affects about 788 million adults worldwide, more than double the number in 1990, making it one of the most widespread and underrecognized health threats A recent systematic analysis published in The Lancet revealed that CKD is now the ninth leading cause of death globally, responsible for roughly 1.48 million deaths in 2023 alone High blood sugar, elevated blood pressure, and excess body weight are the leading drivers of CKD worldwide, together accounting for most of the disease's overall health burden Early-stage CKD affects over 13% of the adult population globally, yet most cases remain undiagnosed because symptoms often don't appear until the disease is advanced You can lower your risk of CKD by keeping your blood pressure and blood sugar in check, getting regular movement, staying hydrated, reducing processed foods, and supporting kidney function with balanced nutrition